Latest Thrombus Stories

Considerable regional differences exist in the treatment of patients with acute cerebral infarction. This is the finding presented by Erwin Stolz and his co-authors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2011; 108[36]: 607). The prognosis for patients with stroke largely depends on a rapid, standardized first response. Across the German federal state of Hesse, there are great differences in the time interval between symptom onset and admission to...

MOUNTAIN VIEW, Calif., Sept. 8, 2011 /PRNewswire/ -- Concentric Medical, Inc., a global leader in acute ischemic stroke intervention, today announced completion of enrollment of the TREVO Study. The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first evaluation of Stentriever(TM) technology in a European, multicenter, prospective clinical trial. The TREVO Study was designed to assess the ability of the Trevo® System to remove...

MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- Concentric Medical, Inc. today announced the full European launch of Trevo® Pro 4 System. This next standard in Stentriever(TM) technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke. The Trevo® Pro 4 system is the next generation of Trevo Stentrievers from Concentric Medical and is used to remove thrombus in stroke patients. It has a unique wide-cell...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantially less bleeding, and also results in lower mortality.  ahe benefits of apixaban are consistent irrespective of how well warfarin is used at different centers, as measure by “time in therapeutic range.” The randomized, double-blind clinical trial known...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantially less bleeding and also results in lower mortality. The results were presented by Duke University Medical Center researchers at the European Society of Cardiology in Paris, France, today, and published simultaneously online in the New England Journal of...

-- GARFIELD Registry Data presented at ESC CONGRESS 2011 provides unique picture of the real global burden of AF -- PARIS, Aug. 28, 2011 /PRNewswire-USNewswire/ -- New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) - medicines known to significantly lower stroke risk in these patients. The findings are from the first cohort of the GARFIELD...

Patients with clinically diagnosed superficial vein thrombosis (SVT), a blood clot in the veins just beneath the skin that commonly resolves on its own without treatment, are four to six times more likely to develop venous thromboembolism (VTE), a dangerous, often life-threatening condition, according to study results published today in Blood, the Journal of the American Society of Hematology (ASH).Recent studies have shown that patients diagnosed with SVT using ultrasound to confirm the...

Patients with irregular heartbeat could benefit from a drug that is easier to administer than the current standard treatmentPatients with an irregular heart beat could benefit from a drug that is easier to administer than the current standard treatment.The condition, which is more common with older age and affects about 800,000 people in the UK, can lead to blood clots forming and significantly increases the risk of stroke.A global study, led by the University of Edinburgh and the Duke...

In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be an attractive alternative to warfarin, the current standard for treatment of atrial fibrillation.The full intention-to-treat analysis, which includes patients who discontinued study drug, showed that rivaroxaban was noninferior to warfarin for...

(Ivanhoe Newswire) -- Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.One goal of the Hopkins research is to increase understanding of how genes regulate the function of platelets, which are the sticky cells in blood that are important to stop excessive bleeding. The...